Information Provided By: 
Fly News Breaks for May 18, 2018
EPZM
May 18, 2018 | 07:36 EDT
Wedbush analyst David Nierengarten raised his price target on Epizyme to $25 from $20, telling investors in a research note that abstracts from The European Hematology Association show responses are deepening in the EZH2-wt follicular lymphoma cohort, increasing his confidence that tazemetostat will find a broad use in FL regardless of mutation status. However, the analyst noted that he is "less certain" on the future for the drug in mesothelioma, where low response rates seen in a Phase 2 trial indicate a more challenging path forward.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
